Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Dimerix Limited ( (AU:DXB) ) is now available.
Dimerix Limited has announced the application for quotation of 212,170 ordinary fully paid securities on the Australian Securities Exchange (ASX), under the code DXB. This move is part of an employee incentive scheme, indicating the company’s efforts to motivate and retain talent, which could positively impact its operational capabilities and market positioning.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.46 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited operates in the biotechnology industry, focusing on the development of innovative pharmaceutical products. The company is involved in creating therapies for unmet medical needs, particularly in the area of kidney disease.
Average Trading Volume: 1,497,148
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$309.1M
For an in-depth examination of DXB stock, go to TipRanks’ Overview page.